[Management of HIT II patients with hirudin antibodies after primary therapy].
Harenberg
J
J
4. Medizinische Klinik, Universitätsklinikum Mannheim, Germany.
D000906:Antibodies / Q000627:therapeutic use*; D000925:Anticoagulants / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006629:Hirudins / Q000276:immunology*; D006801:Humans; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000188:drug therapy*
D000906:Antibodies; D000925:Anticoagulants; D006629:Hirudins; D006493:Heparin